[11C]metomidate PET-CT versus adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient trialXilin Wu, Morris J. Brown, Russell Senanayake et al.|Nature Medicine|2023Cited by 137
Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosterone-producing adenomas presenting in puberty, pregnancy or menopauseMorris J. Brown, Elena Azizan, Claudia Cabrera et al.|Nature Genetics|2021Cited by 88
Outcomes after medical treatment for primary aldosteronism: an international consensus and analysis of treatment response in an international cohortJun Yang, Mitsuhide Naruse, Marta Araujo‐Castro et al.|The Lancet Diabetes & Endocrinology|2025Cited by 53
Molecular Imaging Versus Adrenal Vein Sampling for the Detection of Surgically Curable Primary AldosteronismEmily Goodchild, Morris J. Brown, Xilin Wu et al.|Annals of Internal Medicine|2025Cited by 26
Novel radiolabeled ligand, Para-chloro-2-[<sup>18</sup>F]fluoroethyletomidate (CETO) compared to [<sup>11</sup>C]metomidate-PET (MTO) for the lateralisation of primary aldosteronism (PA)Emily Goodchild, Morris J. Brown, Russell Senanayake et al.|Endocrine Abstracts|2022Cited by 1